Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

A study has found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased ...

it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

A report from The Lancet Diabetes & Endocrinology Commission has proposed new criteria for defining and diagnosing obesity, ...

GLP-1: Glucagon-like peptide-1 ... GLP1-RAs result in an associated increased risk of pancreatitis or medullary thyroid carcinoma. Development of antidrug antibodies are common with the LA ...

A discovery reveals that weight loss drugs like Ozempic and Mounjaro can positively impact 175 diseases and conditions beyond ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...